New TB drug cocktail shows promise in early trial
NCT ID NCT05382312
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an experimental drug called GSK3036656 in combination with other tuberculosis medications in 127 adults with newly diagnosed, drug-sensitive pulmonary TB. Participants received one of several two-drug combinations or standard care for 14 days, then switched to standard treatment. The goal was to measure how quickly the combinations killed TB bacteria in sputum and to check for safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GSK3036656 (an experimental drug) combined with other tuberculosis drugs (bedaquiline, delamanid, BTZ-043, pretomanid, linezolid, moxifloxacin) or standard care
What this could lead to
If successful, this could point toward shorter, more effective treatment combinations for drug-sensitive tuberculosis.
What could go wrong
This is an early Phase 2A trial with only 127 participants and a short 14-day treatment period. Results may not translate to long-term cure or apply to all TB patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Bellville, 7530, South Africa